BB's Stock Haven

[Bansky]

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content

NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD products”.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.